Mariano Ponz-Sarvise

Universidad de Navarra

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (11)

Matthew Reilley

Assistant Professor

University of Virginia School of Medicine

UNITED STATES

View details

Salvador Martín Algarra

Universidad de Navarra

SPAIN

View details

Bruno Sangro

SPAIN

View details

Sara Lopez-Tarruella

ASSOCIATE PROFESSOR

Universidad Complutense de Madrid

SPAIN

View details

Josepmaria Argemi

Adjunct Assistant Professor

University of Pittsburgh

UNITED STATES

View details

Bruno Bockorny

Beth Israel Deaconess Medical Center

UNITED STATES

View details

Daniel Aliseda Jover

Clinica Universidad de Navarra

SPAIN

View details

Angela Lamarca

The University of Manchester

UNITED KINGDOM

View details

Chiara Braconi

University of Glasgow

UNITED KINGDOM

View details

Enrique Conde-Gallastegi

Public University of Navarre

SPAIN

View details

Aram F. Hezel

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mariano Ponz-Sarvise

Research Interests

Explore related searches

Contact this professor

Articles (15)

Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?

Tumor Organoids Grown in Mixed-Composition Hydrogels Recapitulate the Plasticity of Pancreatic Cancers

A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience

Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)

Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.

PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Paradigms on Immunotherapy Combinations with Chemotherapy

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.

The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1<sup>+</sup> tumour-infiltrating lymphocytes.

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All?

Collaborators (11)

Matthew Reilley

Salvador Martín Algarra

Bruno Sangro

Sara Lopez-Tarruella

Josepmaria Argemi

Bruno Bockorny

Daniel Aliseda Jover

Angela Lamarca

Chiara Braconi

Enrique Conde-Gallastegi

Aram F. Hezel

Make your next move.